News & Videos - MORPHIC HOLDING INC.

- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter- -Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027- WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic...

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer. Dr. Cooper is an accomplished leader in drug development with appreciable success and a proven history across all phases of clinical development and in a wide variety of therapeutic areas,...

WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March. 3/6/24 9:10 AM ET GI/Microbiome Panel Discussion at the TD Cowen 44 th Annual Health Care Conference 10:30 AM ET Fireside Chat at the TD Cowen 44 th Annual Health Care Conference 3/13/24 Jefferies...

-Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis (UC)- -Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC- -GARNET phase 2 trial of MORF-057 in Crohn’s disease (CD) expected to begin enrolling in the first half of 2024- -Ended 2023 with $704.3 million in cash and equivalents; cash runway into second half of 2027- WALTHAM, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical...

-Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave- WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., Chief Executive Officer of Morphic, has returned in full capacity from a previously announced temporary medical leave of absence and will present...

WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the upcoming Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference. Jefferies London Healthcare Conference Fireside Chat Date: Tuesday, November 14, 2023 Time: 5:00 PM GMT/12:00 PM ET A live webcast...

-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027- WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new...

LOS ANGELES, CA / ACCESSWIRE / October 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click here...

WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The positive topline results from EMERALD-1 were reported in April of this year...

LOS ANGELES, CA / ACCESSWIRE / October 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click here...

WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Morphic Holdings Inc. (Nasdaq: MORF) today announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is taking a medical leave of absence. Dr. Tipirneni is expected to return to his role as Chief Executive Officer after he recovers. In the interim, Morphic’s executive team, led by Dr. Bruce Rogers, President and Dr. Marc Schegerin, COO and CFO, will continue with its leadership in day-to-day...

LOS ANGELES, CA / ACCESSWIRE / September 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click...

-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures- -Clinical improvement consistently seen across key measures at week 12, mMCS response of 45.7% and endoscopic improvement of 25.7%- -MORF-057 well tolerated with no safety signals observed- -PK/PD confirm results seen in healthy volunteer studies, with median RO >99% and saturation achieved early and sustained at week 12- WALTHAM, Mass., Sept. 22,...

WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Marc Schegerin, MD, COO & CFO, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 6 th at 8:00 AM ET. A live webcast of the event will be available on the Investor section of Morphic’s website at...

-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater than $730 million in cash and equivalents at 6/30/23; extended cash runway into second half of 2027- -New clinical trials of MORF-057 in Crohn’s disease and MORF-088 in myelofibrosis to begin in the first half of 2024- WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq:...

WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the Jefferies Healthcare Conference, including a hosted fireside chat, on Wednesday, June 7, 2023. Fireside Chat Information Date: Wednesday June 7, 2023 Time: 1:00 PM ET A live webcast of the presentation will be available...

WALTHAM, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in a Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023. Fireside Chat Information Date: Wednesday May 17, 2023 Time: 10:30 AM ET A live webcast of the presentations will be...

WALTHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF) today announced the presentation of new preclinical data in the MORF-057 IBD development program that are consistent with previous findings and add new support to mechanistic understanding of the molecule’s activity in a nonhuman primate (NHP) model of ulcerative colitis. The poster presentation was made at Digestive Disease Week (DDW) 2023. “The data presented at DDW continue to refine and reinforce our...

WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today announced the closing of an underwritten public offering of 6,133,334 shares of its common stock at a price to the public of $45.00 per share, which includes 800,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. Morphic...

WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an underwritten public offering of 5,333,334 shares of its common stock at a price to the public of $45.00 per share. The gross proceeds from this offering are expected to be approximately $240.0 million, before deducting underwriting discounts and...